Elevated endogenous cannabinoids in schizophrenia.

  title={Elevated endogenous cannabinoids in schizophrenia.},
  author={F. Markus Leweke and Andrea Giuffrida and Ullrich Wurster and Hinderk M. Emrich and Daniele Piomelli},
  volume={10 8},
Evidence suggests that cannabinoid receptors, the pharmacologcial target of cannabis-derived drugs, and their accompanying system of endogenous activators may be dysfunctional in schizophrenia. To test this hypothesis, we examined whether endogenous cannabinoid concentrations in cerebrospinal fluid of schizophrenic patients are altered compared to nonschizophrenic controls. Endogenous cannabinoids were purified from cerebrospinal fluid of 10 patients with schizophrenia and 11 non-schizophrenic… CONTINUE READING
155 Citations
2 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 155 extracted citations


Publications referenced by this paper.
Showing 1-2 of 2 references

ACKNOWLEDGEMENTS: Funded by grants from the National Institute of Drug Abuse (DA 12447 and DA 12431) and Roche Bioscience to D.P

  • R Mechoulam, E Fride, S Ben-Shabat
  • Eur J Pharmacol 362,
  • 1998

Puri®cation and high-resolution analysis of anandamide and other fatty acylethanolamides

  • A Giuffrida, D. Piomelli
  • Laychock SG and Rubin RP, eds. Lipid Second…
  • 1998
2 Excerpts

Similar Papers

Loading similar papers…